Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma.
Interferon (IFN) therapy decreases the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV). One hundred and fifty-nine consecutive patients who underwent liver resection for HCV-related HCC were studied. In 17 (group 1) of the 159 patients, HCC was detected during or after IFN therapy. The incidences of recurrence after surgery in the group 1 patients and the other 142 patients (group 2) were compared. Eight patients had a complete response to IFN, 4 had a partial response, and 5 had no response. The proportion of patients without HCV viremia was significantly higher in the group 1 patients (P < 0.0001). The tumor-free survival rate was significantly higher in the group 1 patients (P = 0.0010). By multivariate analysis of various risk factors for recurrence, no previous IFN was a significant independent risk factor for recurrence (risk ratio = 6.336; 95%CI, 1.512 - 26.50). The patients with HCC who underwent IFN therapy previously are good candidates for liver resection because recurrence after the operation was rarely observed.
Kubo
S
S
Second Department of Surgery, Osaka City University Medical School, Abeno-ku, Osaka 545-8585, Japan. m7696493@msic.med.osaka-cu.ac.jp
Nishiguchi
S
S
Hirohashi
K
K
Tanaka
H
H
Tsukamoto
T
T
Shuto
T
T
Takemura
S
S
Yamamoto
T
T
Ikebe
T
T
Wakasa
K
K
Shiomi
S
S
Kinoshita
H
H
D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000601:surgery / Q000821:virology; D018572:Disease-Free Survival; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery / Q000821:virology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000821:virology*; D012189:Retrospective Studies; D012307:Risk Factors
D000998:Antiviral Agents; D016898:Interferon-alpha